TRIAP1 Knockdown Sensitizes Non-small Cell Lung Cancer to Ionizing Radiation by Disrupting Redox Homeostasis
Overview
Pulmonary Medicine
Authors
Affiliations
Background: Radioresistance of some non-small cell lung cancer (NSCLC) types increases the risk of recurrence or metastasis in afflicted patients, following radiotherapy. As such, further improvements to NSCLC radiotherapy are needed. The expression of oncogene TP53-regulated inhibitor of apoptosis 1 (TRIAP1) in NSCLC is increased following irradiation. Furthermore, gene set enrichment analysis (GSEA) has suggested that TRIAP1 might be involved in maintaining redox homeostasis. This in turn might enhance cell radioresistance.
Methods: In this study we irradiated human NSCLC cell lines (A549 and H460), while knocking down TRIAP1, to determine whether a disrupted redox homeostasis could attenuate radioresistance.
Results: Irradiation notably increased both mRNA and protein levels of TRIAP1. In addition, TRIAP1 knockdown decreased the expression of several antioxidant proteins, including thioredoxin-related transmembrane protein (TMX) 1, TMX2, thioredoxin (TXN), glutaredoxin (GLRX) 2, GLRX3, peroxiredoxin (PRDX) 3, PRDX4, and PRDX6 in A549 and H460 cells. In addition, silencing TRIAP1 impaired the radiation-induced increase of the aforementioned proteins. Continuing along this line, we observed a radiation-induced reduction of cell viability and invasion, as well as increased apoptosis and intracellular reactive oxygen species following TRIAP1 knockdown.
Conclusions: In summary, we identified TRIAP1 as a key contributor to the radioresistance of NSCLC by maintaining redox homeostasis.
Matrix-free human lung organoids derived from induced pluripotent stem cells to model lung injury.
Budeus B, Kroepel C, Stasch L, Klein D Stem Cell Res Ther. 2024; 15(1):468.
PMID: 39696649 PMC: 11657174. DOI: 10.1186/s13287-024-04106-3.
Liu G, Shi H, Zheng H, Kong W, Cheng X, Deng L Clin Respir J. 2024; 18(8):e13801.
PMID: 39135128 PMC: 11319089. DOI: 10.1111/crj.13801.
Geng N, Qi Y, Qin W, Li S, Jin H, Jiang Y BMC Pulm Med. 2023; 23(1):259.
PMID: 37452310 PMC: 10347730. DOI: 10.1186/s12890-023-02538-w.
Targeting the p53 signaling pathway in cancers: Molecular mechanisms and clinical studies.
Shen J, Wang Q, Mao Y, Gao W, Duan S MedComm (2020). 2023; 4(3):e288.
PMID: 37256211 PMC: 10225743. DOI: 10.1002/mco2.288.
The Role of Peroxiredoxins in Cancer Development.
Thapa P, Jiang H, Ding N, Hao Y, Alshahrani A, Wei Q Biology (Basel). 2023; 12(5).
PMID: 37237480 PMC: 10215932. DOI: 10.3390/biology12050666.